BR112023006143A2 - Composição farmacêutica para prevenir ou tratar doença hepática colestática, contendo beta-lapachona como ingrediente ativo - Google Patents

Composição farmacêutica para prevenir ou tratar doença hepática colestática, contendo beta-lapachona como ingrediente ativo

Info

Publication number
BR112023006143A2
BR112023006143A2 BR112023006143A BR112023006143A BR112023006143A2 BR 112023006143 A2 BR112023006143 A2 BR 112023006143A2 BR 112023006143 A BR112023006143 A BR 112023006143A BR 112023006143 A BR112023006143 A BR 112023006143A BR 112023006143 A2 BR112023006143 A2 BR 112023006143A2
Authority
BR
Brazil
Prior art keywords
preventing
liver disease
lapachone
pharmaceutical composition
active ingredient
Prior art date
Application number
BR112023006143A
Other languages
English (en)
Inventor
Seog Yoon Joo
Sik Seo Kang
Su Han Jeong
Je Moon Sung
Hoon Lee Jung
Bin Yoon Soo
Original Assignee
Curome Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curome Biosciences Co Ltd filed Critical Curome Biosciences Co Ltd
Publication of BR112023006143A2 publication Critical patent/BR112023006143A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium

Abstract

A presente invenção refere-se a uma composição farmacêutica para prevenir ou tratar doença hepática colestática, contendo ß-lapachona como um ingrediente ativo, e pode fornecer um agente para prevenir e tratar eficazmente a doença hepática colestática.
BR112023006143A 2020-10-08 2021-10-06 Composição farmacêutica para prevenir ou tratar doença hepática colestática, contendo beta-lapachona como ingrediente ativo BR112023006143A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200130028 2020-10-08
PCT/KR2021/013732 WO2022075756A1 (ko) 2020-10-08 2021-10-06 베타-라파촌을 유효성분으로 포함하는 담즙 정체성 간질환 예방 또는 치료용 약학 조성물

Publications (1)

Publication Number Publication Date
BR112023006143A2 true BR112023006143A2 (pt) 2023-05-09

Family

ID=81126679

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023006143A BR112023006143A2 (pt) 2020-10-08 2021-10-06 Composição farmacêutica para prevenir ou tratar doença hepática colestática, contendo beta-lapachona como ingrediente ativo

Country Status (10)

Country Link
US (3) US20240115545A1 (pt)
EP (1) EP4023220A4 (pt)
JP (1) JP7411875B2 (pt)
KR (2) KR102393676B1 (pt)
CN (1) CN114630662A (pt)
AU (1) AU2021358793A1 (pt)
BR (1) BR112023006143A2 (pt)
CA (1) CA3153516A1 (pt)
MX (1) MX2023003401A (pt)
WO (1) WO2022075756A1 (pt)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2556794A1 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone as a broad spectrum anti-cancer agent
AU2006214892B2 (en) * 2005-02-16 2013-06-27 Kt & G Co., Ltd Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
CN101822659A (zh) * 2010-05-11 2010-09-08 中国药科大学 秋水仙碱在制备治疗胆汁淤积性肝病药物中的应用
CA2907230A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
KR20220013459A (ko) * 2013-10-25 2022-02-04 악셀레론 파마 인코포레이티드 섬유화 질환을 치료하기 위한 엔도글린 펩티드
EP3092231B1 (en) * 2013-12-11 2018-06-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
KR101501612B1 (ko) 2014-07-25 2015-03-12 충남대학교산학협력단 베타-라파콘을 함유하는 만성 골수성 백혈병 예방용 또는 치료용 조성물
KR20160081588A (ko) 2014-12-31 2016-07-08 이화여자대학교 산학협력단 베타 라파콘 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 뇌손상 보호 또는 퇴행성 뇌질환 예방 및 치료용 조성물
KR101752697B1 (ko) * 2015-04-17 2017-07-03 (주)나디안바이오 나프토퀴논계 화합물을 유효성분으로 포함하는 췌장염 예방 및 치료용 조성물
CN105056230A (zh) * 2015-08-03 2015-11-18 中国医学科学院医学生物学研究所 β-拉帕醌的应用及含有β-拉帕醌的复合佐剂和疫苗
KR101845862B1 (ko) * 2015-11-11 2018-04-06 (주)나디안바이오 특발성 폐섬유증의 치료 또는 예방을 위한 약학적 조성물
US10682344B2 (en) * 2016-06-03 2020-06-16 Chemocentryx, Inc. Method of treating liver fibrosis

Also Published As

Publication number Publication date
KR20220051323A (ko) 2022-04-26
WO2022075756A1 (ko) 2022-04-14
CN114630662A (zh) 2022-06-14
KR102393676B1 (ko) 2022-05-04
EP4023220A4 (en) 2024-02-14
MX2023003401A (es) 2023-04-25
KR20220047178A (ko) 2022-04-15
US20220331288A1 (en) 2022-10-20
JP7411875B2 (ja) 2024-01-12
US20230055593A1 (en) 2023-02-23
EP4023220A1 (en) 2022-07-06
US20240115545A1 (en) 2024-04-11
AU2021358793A1 (en) 2022-05-12
CA3153516A1 (en) 2022-04-08
JP2023501058A (ja) 2023-01-18

Similar Documents

Publication Publication Date Title
DOP2019000117A (es) Nuevos derivados de quinolina
BR112012006686B8 (pt) compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa
CO2017011536A2 (es) Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
UY37789A (es) Nuevos derivados de azaquinolina
UY37831A (es) Nuevos derivados de quinolina
BR112019024264A2 (pt) Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer
BR112018008805A2 (pt) proteínas de função dupla e composição farmacêutica que compreende a mesma
BR112017012327A2 (pt) benzamidas substituídas por 1,3-tiazol-2-il.
BR112022001324A2 (pt) Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
BR112012031580A2 (pt) derivado de tetra-hidrocarbolina
BR112018072545A2 (pt) inibidores da arginase e suas aplicações terapêuticas
CL2023002383A1 (es) Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d
BR112012010786A2 (pt) udo de derivados de benzo-heterociclo para medir e tratar câncer ou para inibir metástase de câncer
BR112017026294A2 (pt) formulação em gel tópica farmacêutica, e, método para tratar ou prevenir uma doença ou condição.
CL2020002891A1 (es) Nuevos derivados de quinolina
CO2019011877A2 (es) Nuevos derivados de pirazol bicíclicos
CR20150505A (es) Derivado de dihidropiridazin-3,5-diona
BR112017006406A2 (pt) composições e métodos para o tratamento e profilaxia de infecções de sítio cirúrgico
CO2020001242A2 (es) Dihidrooxadiazinonas
BR112021019262A2 (pt) Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose
BR112019025030A2 (pt) Preparação umidificante tópica.
BRPI0916885B8 (pt) composição farmacêutica
ECSP20023626A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
BR112014031649A8 (pt)

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: VIDE PARECER